Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium 177Lu vipivotide tetraxetan AAA617 versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen PSMA positive Oligometastatic Prostate Cancer OMPC
Study Type: Treatment
Phase: III
NCTID: NCT05939414
Principal Investigator:
Xinglei Shen
HoLEP prior to Radiation Therapy for Patients with LUTS/Retention and Concurrent Prostate Cancer
Study Type: Supportive Care
Phase: N/A
NCTID: NCT03802851
Principal Investigator:
Bristol Whiles
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
Study Type: Supportive Care
Phase: III
NCTID: NCT05838716
Principal Investigator:
Elizabeth Wulff
Docetaxel addition in Metastatic Castrate-Sensitive Prostate Cancer ASPIRE
Study Type: Treatment
Phase: III
NCTID: NCT06931340
Principal Investigator:
Elizabeth Wulff
The Phase III ?High Five Trial? Five Fraction Radiation For High-Risk Prostate Cancer
Study Type: Treatment
Phase: III
NCTID: NCT05946213
Principal Investigator:
Jay Shiao
The Role of Androgen Deprivation Therapy In CArdiovascular Disease ? A Longitudinal Prostate Cancer Study RADICAL PC1 and A RAndomizeD Intervention for CArdiovascular and Lifestyle Risk Factors in Prostate Cancer Patients RADICAL PC2
Study Type: Prevention
Phase: IV
NCTID: NCT03127631
Principal Investigator:
Charles Porter
Implementation and Evaluation of SCIPI: A Multi-Site Pilot Randomized Controlled Trial to Improve Decision-Making and Quality of Life Among Patients with Localized Prostate Cancer
Study Type: Other
Phase: N/A
NCTID: NCT07280897
Principal Investigator:
William Parker
Quantifying Optimal Relugolix Duration with Radiation in High Risk Prostate Cancer QURE-PC
Study Type: Treatment
Phase: II
NCTID: NCT06129851
Principal Investigator:
Xinglei Shen
AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer
Study Type: Treatment
Phase: III
NCTID: NCT06855277
Principal Investigator:
Xinglei Shen
PSMAcTION: A phase II/III, open-label, international, multicenter, randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy.
Study Type: Treatment
Phase: II/III
NCTID: NCT06780670
Principal Investigator:
Xinglei Shen